AB023 reduces dialyzer clotting compared to placebo during heparin-free dialysis, and continues to be safe and well tolerated

Presentation to include clinical data from Aronora's phase 2 study of AB023, a factor XI-targeted antibody that is being developed for the treatment and prevention of thrombosis and inflammation.

Enzyme that selectively targets blood clots has received FDA Fast Track designation, allowing for expedited clinical development

EMR's latest publications provide an exceptional tool to understand the current trends, therapeutic structure, competitive landscape and the outlook for key emerging antithrombotic drug markets till 2016.